Tonix Pharmaceuticals Holding 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thanks so much, everyone, for joining us this year for the Guggenheim Healthcare Innovation Conference. I'm Vamil Divan, one of the biopharma analysts here. Next up here in this room, we have Tonix Pharmaceuticals, and I'm joined by Seth Lederman, the CEO of the company. Thanks again for joining us. Maybe I'll turn it to you first, I know you just reported earnings yesterday morning. I'm keeping my days straight here. Maybe just the key takeaways that you're highlighting from the results you shared.
First of all, thank you very much for including us in the conference and for interviewing me. We did report yesterday our earnings, and I think the headline was that our launch of TONMYA for treating fibromyalgia is on track. We had growth in net sales, all of our KPIs, net sales, TRx, NRx, refills, NBRx, et cetera, MBRx. So, we're really on track for what we think is going to be a very important product in fibromyalgia. There hasn't been a product in fibromyalgia, a new product in more than 15 years. So, we've had to come in and recreate, breathe life into this category, which is a challenge.
Yeah. But on the other hand, there's really wind at our back because there's a lot of science that's happened in the past 15 years and a lot of interest in fibromyalgia.
Okay. You touched on this briefly, but what are the key metrics that you're looking at? What should investors be focused on as we track this launch?
Yeah. Well, the main thing is net sales.
Right. We had $15 million of net sales last quarter, and that was over $11 million of net sales in Q2, so that was a 37% increase.
TRx grew significantly, 27%, and all the way down. But in addition to that, behind that, we had wins in access. In Q2, we got two of the big three payers in commercial, and then in Q3, we got two of the big three in managed Medicare. As we sit here today, we have 53% of covered lives in the U.S., and we believe that contributed to Q3 sales, but we expect going forward that that will be further wind at our back. Another important change is over the summer, we recruited and trained 50 new sales representatives who were in the field on September 1st, so our sales force has grown from 100 to 150.
Our commercial operation is running on all cylinders. Yesterday, we sponsored an unbranded segment on "Good Morning America" to raise awareness of fibromyalgia. Both on the unbranded and the branded piece and all over, I think that we're having wins and successes in fibromyalgia.
Okay. You mentioned the access that you have now, I think you said 166 million lives covered?
Yes. Couple questions from there.
What do you think is next here? What is the sort of steady state you hope to get to in terms of covered lives? What is the level of access? Are there step throughs or what do patients have to do to actually get on the product?
Yeah. I think the same reasons that the current payers have signed on are the same reasons why new payers will sign on, meaning I think a typical experience is that a plan will see that they are paying for prescriptions and they are not getting a rebate. That is usually something that brings people to the table. From the launch, from the very beginning of the launch, actually almost a year ago today, we have had very good rates on prior auth submissions and prior auth approvals. I think that that is what is really driving our success. Where do I hope it gets to? Well, I think that we still have one of the big three to get in commercial and one of the big three to get in managed Medicare.
There are some other plans that are not part of the big three, but together a lot of lives. I cannot guide, and obviously we cannot drag anyone to the table, but we are having a lot of productive conversations, and our managed access team is running all over the country, not just focused on the top plans, but also the sub-plans now.
Yeah. Because once you get the top plan, you still have to get the sub-plans to buy on.
In terms of the steps, we have not focused on getting coverage without steps. It just has not been a priority for us. So typically, our contracts would have one or two steps, and it is usually a list of the three approved medicines and then maybe one or two off-label medicines that are commonly used. But we do not see that as an obstacle to our product being used. Part of that is it is just the way of life today in the industry, but the other thing is that fibromyalgia patients, particularly the group of fibromyalgia patients who are already diagnosed, typically have already been on and failed one of the existing products.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
